---
document_datetime: 2023-09-21 17:56:43
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps/kaletra-epar-procedural-steps-taken-authorisation_en.pdf
document_name: kaletra-epar-procedural-steps-taken-authorisation_en.pdf
version: success
processing_time: 0.3734871
conversion_datetime: 2025-12-28 11:57:39.4519
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## BACKGROUND INFORMATION ON THE PROCEDURE

## 1. Submission of the dossier

The applicant Abbott Laboratories Limited submitted on 27 June 2000 an application for Marketing Authorisation to the European Agency for the Evaluation of Medicinal Products (EMEA) for Kaletra, through  the  centralised  procedure.  After  agreement  by  the  CPMP  on  21  December  1999,  this medicinal product has been referred to Part B of the Annex to Council Regulation No (EEC) 2309/93 of 22 July 1993.

The Rapporteur and Co-Rapporteur appointed by the CPMP were:

Rapporteur:

Dr. Eric Abadie

Co-Rapporteur:

Dr. Jean-Louis Robert

## Licensing status:

The product was not licensed in any country at the time of submission of the application. Kaletra was granted a license in the United States on 15 September 2000.

## 2. Steps taken for the assessment of the product

- The procedure started on 18 July 2000.
- The Rapporteur's first assessment report was circulated to all CPMP Members on 29 September 2000. The Co-Rapporteur's first assessment report was circulated to all CPMP Members on 26 September 2000.
- The summary report of the inspection carried out at the manufacturing site RP Scherer between 31 July-3 August 2000 by the Medicines Control Agency, was issued on 19 September 2000.
- During  the  meeting  on  14-16  November  2000,  outstanding  issues  were  addressed  by  the applicant during a hearing before the CPMP.
- The CPMP agreed on the consolidated list of questions to be sent to the applicant. The final consolidated list of questions was sent to the applicant on 16 November 2000 .
- The  applicant  submitted  the  responses  to  the  CPMP  consolidated  list  of  questions  on  24 November 2000.
- The Rapporteur circulated the joint assessment report on the applicant's responses to the list of questions to all CPMP Members on 4 December 2000.
- The  Rapporteur  circulated  an  assessment  report  on  the  Purkinje  Fibers  study  to  all  CPMP Members on 11 December 2000.
- During  the  meeting  on  12-14  December  2000,  the  CPMP,  in  the  light  of  the  overall  data submitted  and  the  scientific  discussion  within  the  Committee,  issued  a  positive  opinion  for granting  a  Marketing  Authorisation  under  exceptional  circumstances  to  Kaletra  soft  capsules and oral solution on 14 December 2000. The applicant provided a letter of undertaking of the specific obligations and follow-up measures to be fulfilled post-authorisation on 13 December 2000.
- The EMEA forwarded the opinion to the European Commission who issued on 20 March 2001 the respective Decision for granting a Marketing Authorisation under exceptional circumstances to Kaletra soft capsules and oral solution.